The dose of IFNα-Le used in both the rat and mouse model was slightly higher than the dose chosen for a cutaneous melanoma study (Stadler et al. 2006), but is in line with the current practice for IFNα-2b treatment of chronic myeloid leukemia and chronic hepatitis B (Online Resources). Here, IFNA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.